TORONTO, ON / ACCESSWIRE / July 8, 2024 / Theralase® Technologies Inc. ('Theralase®' or the 'Company') (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ('PDCs') for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement ('NBPP') offering ('Offering') of units ('Units')..

多伦多，ON/ACCESSWIRE/2024年7月8日/Theralase®Technologies Inc.（“Theralase®”或“公司”）（TSXV:TLT）（OTCQB:TLTFF）是一家临床阶段制药公司，致力于研究和开发光和/或辐射激活的光动力化合物（“pDC”），以安全有效地破坏各种癌症，细菌和病毒，很高兴地宣布，它已经成功完成了其第一批非经纪私人配售（“NBPP”）单位（“单位”）的发行（“）。。

On closing, the Corporation issued an aggregate of 3,522,729 Units at a price of $CAN 0.22 per Unit for aggregate gross proceeds of $CAN 775,000.

收盘时，该公司发行了总计3522729个单位，价格为每单位0.22加元，总收益为775000加元。

Each Unit consists of one common share of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.30 per share for a period of 5 years following the date of issuance.

每个单位由一份公司普通股（“普通股”）和一份普通股认购权证（“认股权证”）组成。每份认股权证使持有人有权在发行日期后的5年内以每股0.30加元的行权价格购买额外的普通股。

The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer ('NMIBC') clinical study currently underway, preclinical research and development of Rutherrin®, working capital and general corporate purposes.

该公司计划将融资收益用于推进目前正在进行的II期非肌肉浸润性膀胱癌（“NMIBC”）临床研究、Rutherrin®的临床前研究和开发、营运资金和一般企业用途。

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended ('U.S. Securities Act'), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S.

本新闻稿中提及的证券尚未且将不会根据经修订的《1933年美国证券法》（“美国证券法”）或美国任何州的任何适用证券法进行登记，并且不得在美国境内或为美国的利益或账户提供或出售。

persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful, including the United States..

除非根据《美国证券法》和任何其他适用的美国证券法进行了注册，或者可以免除此类注册要求，否则人员（该术语在《美国证券法》S条例中定义）或在美国境内的人员。本新闻稿不构成出售要约或招揽购买要约，也不构成在包括美国在内的任何非法出售、招揽或出售的司法管辖区出售所提供的证券。。

All securities issued under the Offering will be subject to a four month and one day hold period from the closing date under applicable Canadian securities laws, which expires on November 6th, 2024. The Offering is subject to receipt of final acceptance from the TSX Venture Exchange.

根据适用的加拿大证券法，本次发行发行的所有证券自交割日起将有四个月零一天的持有期，有效期至2024年11月6日。。

About Theralase® Technologies Inc.:

关于Theralase®Technologies Inc.：

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses..

Theralase®是一家临床阶段制药公司，致力于研究和开发光活化化合物及其相关药物制剂和激活它们的光系统，其主要目标是有效性，次要目标是破坏各种癌症，细菌和病毒的安全性。。

Additional information is available at www.theralase.com and www.sedar.com

更多信息请访问www.theralase.com和www.sedar.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX风险交易所及其监管服务提供商（该术语在TSX风险交易所的政策中定义）均不对本版本的充分性或准确性承担责任。

Forward Looking Statements:

前瞻性声明：

This news release contains 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such statements include; but are not limited to statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Forward looking statements may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's Photo Dynamic Compounds and their drug formulations, preclinical research, clinical studies and regulatory approvals..

本新闻稿包含适用加拿大证券法意义上的“前瞻性声明”。；但不限于关于公司关于光动力化合物及其药物制剂的拟议开发计划的声明。前瞻性陈述可以通过使用“可能”、“应该”、“将会”、“预期”、“相信”、“计划”、“预期”、“估计”、“潜力”等类似表达来识别；包括与公司管理层目前对公司光动力化合物及其药物制剂的未来研究、开发和商业化的期望、临床前研究、临床研究和监管批准有关的声明。。

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to: adequately fund and secure the requisite regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available or may not be available on terms that are commercially favorable to the Company, the risk that the Company's drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings.

这些报表涉及重大风险、不确定性和假设；包括：公司有能力：为及时成功完成第二阶段NMIBC临床研究并实施其发展计划提供充足资金并获得必要的监管批准。其他风险包括：公司成功商业化其药物制剂的能力，可能无法获得足够资金来资助公司运营的风险，或可能无法以对公司有利的商业条款获得资金的风险，公司药物制剂可能无法有效抵抗其临床研究中测试的疾病的风险，公司未能遵守与第三方的许可协议条款并因此失去在其业务中使用关键知识产权的权利的风险，公司保护其知识产权的能力，提交，接受和批准监管文件的时间和成功率。

Many of these factors that will determine actual results are beyond the Company's ability to control or predict..

许多决定实际结果的因素超出了公司的控制或预测能力。。

Readers should not unduly rely on these forward- looking statements, which are not a guarantee of future performance. There can be no assurance that forward looking statements will prove to be accurate as such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements..

读者不应过度依赖这些前瞻性陈述，因为这些陈述并不能保证未来的表现。无法保证前瞻性陈述将被证明是准确的，因为此类前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果或未来事件与前瞻性陈述存在重大差异。。

Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements..

尽管新闻稿中包含的前瞻性声明是基于管理层目前认为合理的假设，但公司无法向潜在投资者保证实际结果、业绩或成就将与这些前瞻性声明一致。。

All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

所有前瞻性声明均于本协议签署之日作出，并可能发生变更。除法律要求外，公司不承担更新此类报表的义务。

For More Information:

有关更多信息：

1.866.THE.LASE (843-5273)

1.866。激光器（843-5273）

416.699.LASE (5273)

416699.酶（5273）

www.theralase.com

www.theralase.com

Kristina Hachey, CPA

Kristina Hachey，注册会计师

Chief Financial Officer

首席财务官

khachey@theralase.com

khachey@theralase.com

SOURCE: Theralase Technologies, Inc.

资料来源：Theralase Technologies，Inc。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿